SCM
Suvretta Capital Management Portfolio holdings
AUM
$2.65B
1-Year Return
18.59%
This Quarter Return
+11.78%
1 Year Return
+18.59%
3 Year Return
+180.23%
5 Year Return
+278.12%
10 Year Return
+1,101.07%
AUM
$2.79B
AUM Growth
+$336M
(+14%)
Cap. Flow
+$64.9M
Cap. Flow
% of AUM
2.33%
Top 10 Holdings %
Top 10 Hldgs %
40.95%
Holding
113
New
14
Increased
21
Reduced
19
Closed
15
Top Buys
| 1 |
Benitec Biopharma
BNTC
|
$65.6M |
| 2 |
Starbucks
SBUX
|
$53.6M |
| 3 |
Capital One
COF
|
$35.3M |
| 4 |
CrowdStrike
CRWD
|
$34.3M |
| 5 |
BIOA
BioAge Labs, Inc. Common Stock
BIOA
|
$30.3M |
Top Sells
| 1 |
Arcellx
ACLX
|
$69M |
| 2 |
Insmed
INSM
|
$64.7M |
| 3 |
Ultragenyx Pharmaceutical
RARE
|
$50.6M |
| 4 |
Elevance Health
ELV
|
$49.5M |
| 5 |
Sysco
SYY
|
$37.2M |
Sector Composition
| 1 | Healthcare | 59.5% |
| 2 | Technology | 11.2% |
| 3 | Consumer Discretionary | 8.56% |
| 4 | Communication Services | 7.2% |
| 5 | Financials | 5.28% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
51
Sanofi
SNY
$112B
| $10.1M | 0.32% |
174,901
-35,800
| -17% | -$2.06M |
|
52
scPharmaceuticals
SCPH
$299M
| $9.34M | 0.3% |
+2,049,009
| New | +$9.34M |
|
|
MRNS
53
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $8.93M | 0.29% |
5,073,913
+1,253,901
| +33% | +$2.21M |
|
54
InflaRx
IFRX
$106M
| $8.77M | 0.28% |
5,733,910
| – | – |
|
55
KraneShares CSI China Internet ETF
KWEB
$8.43B
| $7.82M | 0.25% |
+230,000
| New | +$7.82M |
|
56
iShares China Large-Cap ETF
FXI
$6.54B
| $7.71M | 0.25% |
+242,500
| New | +$7.71M |
|
57
GE HealthCare
GEHC
$33.4B
| $7.04M | 0.23% |
75,000
| – | – |
|
58
Exact Sciences
EXAS
$9.79B
| $6.41M | 0.21% |
94,100
| – | – |
|
59
Biogen
BIIB
$20.3B
| $5.8M | 0.19% |
+29,946
| New | +$5.8M |
|
60
Kezar Life Sciences
KZR
$28.3M
| $5.54M | 0.18% |
716,759
| – | – |
|
61
Teva Pharmaceuticals
TEVA
$21.4B
| $4.83M | 0.15% |
268,100
| – | – |
|
62
Danaher
DHR
$141B
| $4.57M | 0.15% |
16,427
| – | – |
|
63
Thermo Fisher Scientific
TMO
$183B
| $4.49M | 0.14% |
7,260
| – | – |
|
64
Fulcrum Therapeutics
FULC
$349M
| $4.22M | 0.14% |
1,182,791
-1,358,255
| -53% | -$4.85M |
|
65
Kenvue
KVUE
$39B
| $3.97M | 0.13% |
171,596
| – | – |
|
66
Abbott
ABT
$232B
| $3.82M | 0.12% |
33,520
| – | – |
|
67
Alnylam Pharmaceuticals
ALNY
$59.6B
| $3.8M | 0.12% |
13,824
-23,800
| -63% | -$6.55M |
|
68
Elanco Animal Health
ELAN
$8.61B
| $3.73M | 0.12% |
253,600
| – | – |
|
69
Mettler-Toledo International
MTD
$26.3B
| $2.95M | 0.09% |
1,964
| – | – |
|
70
Cencora
COR
$57.2B
| $2.81M | 0.09% |
12,488
| – | – |
|
71
Intuitive Surgical
ISRG
$162B
| $2.55M | 0.08% |
5,200
| – | – |
|
72
DexCom
DXCM
$31.5B
| $2.12M | 0.07% |
31,680
+25,800
| +439% | +$1.73M |
|
|
MOLN
73
Molecular Partners
MOLN
$144M
| $2.03M | 0.07% |
400,000
| – | – |
|
74
Avantor
AVTR
$8.86B
| $1.86M | 0.06% |
71,850
| – | – |
|
75
IQVIA
IQV
$31B
| $1.7M | 0.05% |
7,175
| – | – |
|